[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-infarction-mi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-infarction-mi":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,49,82,107,139,163,198,225,251,283,306,338,369,396,424,451,485,523,550,581,605,630,656,683,704],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100585575","health-coaching-for-patients-with-cardiovascular-disease-100585575",false,"NCT06904144","Health Coaching for Patients With Cardiovascular Disease","Health Coaching for Patients With Cardiovascular Disease: A Mixed-Methods Evaluation of the Impact on Patient Outcomes and Provider Satisfaction and Acceptability","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosis of coronary artery disease resulting in myocardial infarction and\u002For congestive heart failure\n* physical condition effectively managed by routine healthcare and not requiring urgent medical attention\n* ability to communicate in English\n* access to a working phone or computer and ability to communicate via phone or computer.\n\nExclusion Criteria:\n\n* Patients who have had chest coronary artery bypass surgery\n* Documented cognitive and\u002For major psychiatric disorders, including dementia, Alzheimer's, depression or anxiety uncontrolled by anxiolytic, anti-psychotic, and\u002For anti-depressants and\u002For PHQ-9 score 15-27 and GAD-7 score \\>15\n* current alcohol or drug dependency\n* resident of extended care\u002Fskilled facility\n* prisoners or ward of state.","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","For patients discharged with a diagnosis of cardiovascular disease coronary artery disease resulting in myocardial infarction and\u002For congestive heart failure, this study will evaluate if the addition of 12 virtual health coaching sessions over the course of 16 weeks will improve physiological, psychological, and social health outcomes, prove acceptable and satisfactory for these patients with CVD, decrease CVD-related questions and concerns sent to the provider via MyChart, and reduce hospital readmission rates over a 90-day period as compared to patients discharged with the same diagnosis who receive standard post-discharge care. The study will also evaluate the perceptions of physician and advanced practice providers related to the health coach as part of the interprofessional team and the amount of time spent addressing CVD-related patient questions and concerns via MyChart messages.",[27,28,29,30],"Congestive Heart Failure Treated","Myocardial Infarction (MI)","Coronary Artery Disease","Congestive Heart Failure Chronic",[32,33,34,35],"health coaching","coronary artery disease","congestive heart failure","myocardial infarction","NOT_YET_RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":42,"type":21},"2026-10-01",{"date":44,"type":21},"2028-10-01",{"name":46,"class":47},"Ohio State University","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":78,"leadSponsor":80,"locationsCount":48},"100641603","abbreviated-antithrombotic-therapy-after-pci-in-patients-with-af-and-ami-100641603","NCT07583784","Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI","Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction","HERO-AF-AMI","Inclusion Criteria:\n\n1. Patients aged 19 years old\n2. Patients with AF and CHA2DS2-VA score ≥2.\n3. ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)\n\n   * STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12\n   * NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12\n\n     1. Symptoms of ischemia.\n     2. New or presumed new significant ST-T wave changes\n     3. Development of pathological Q waves on electrocardiography.\n     4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.\n     5. Intracoronary thrombus detected on angiography.\n4. Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.\n\nExclusion Criteria:\n\n1. Patients contraindicated for use of DOACs or clopidogrel\n2. Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist\n3. Planned cardiac surgery within 1 year after randomization\n4. Patients with severe thrombocytopenia or coagulopathy\n5. Liver cirrhosis or severe hepatic dysfunction\n6. Advanced chronic kidney disease (creatinine clearance \\\u003C15 ml\u002Fmin\u002F1.73 m2) or on dialysis\n7. Prior history of intracranial hemorrhage\n8. Coexisting conditions related to high risk of life-threatening bleeding\n9. Pregnancy or breast feeding\n10. Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n11. Unwillingness or inability to comply with the procedures described in this protocol.","19 Years",{"count":59,"type":21},860,[24],"The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).",[28,63,64,65],"ST-Segment Elevation Myocardial Infarction(STEMI)","NSTEMI - Non-ST-Segment Elevation Myocardial Infarction","AF - Atrial Fibrillation",[67,68,69,70,71,72,73],"AF","Myocardial infarction","STEMI","NSTEMI","DOAC","NOAC","OAC alone","2026-06-15",{"date":76,"type":40},"2026-06-17",{"date":39,"type":21},{"date":79,"type":21},"2032-12-31",{"name":81,"class":47},"Chonnam National University Hospital",{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100634886","odssey-scdidentification-of-markers-to-predict-the-risk-of-sudden-cardiac-death-in-moderated-lvef-in-ischemic-cardiomyopathy-100634886","NCT07545512","ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY","ODISSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY (ODISSEY-SCD","ODISSEY","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Hospitalized for acute STEMI within 6 months (Type 1 myocardial infarction according to ESC recommendations, Thygesen EHJ 2018).\n* Left ventricular ejection fraction between 35% and 50% at least 40 days after acute myocardial infarction (see above).\n* Under optimal tolerated medical treatment.\n* Covered by a social security scheme.\n* Legally competent to give voluntary informed consent to participate in the study.\n* Patient who will not participate in further studies involving an investigational drug or device until the end of the trial (i.e. 60 months). Participation in registries is authorized\n\nExclusion Criteria:\n\n* Presence of a secondary prevention indication for implantation of an implantable automatic defibrillator (ICD)\n* Presence of a pacemaker\n* Administration of ventricular antiarrhythmic drugs other than beta-blockers (i.e. amiodarone, sotalol, flecainide)\n* Patients with systemic diseases (cancer, liver failure or end-stage renal disease)\n* Patients with assessed life expectancy \\\u003C 1 year.\n* Age \\> 80\n* Adult patient under legal protection (guardianship, curatorship or other legal protection measure)\n* The subject is pregnant or nursing or positive beta HCG for women of childbearing age\n* Patient participating in another clinical research protocol involving an investigational drug or device within the last 30 days (participation in a registry is permitted at the same time).","80 Years",{"count":92,"type":21},400,[24],"Although advances in treatment and patient management have considerably improved post-infarction prognosis, the risk of sudden cardiac death remains a major concern. Sudden cardiac death (SCD) is defined as an unexpected death occurring within one hour of the onset of symptoms, often of arrhythmic origin. In patients who have survived a myocardial infarction, sudden death represents a persistent threat. This risk is often associated with complications such as left ventricular dysfunction, malignant ventricular arrhythmias, and structural alterations of the myocardium, all of which can favor the development of fatal cardiac events. Among the risk factors identified, reduced left ventricular ejection fraction, a history of ventricular arrhythmias and the presence of extensive scarring of the myocardium are particularly significant.\n\nAssessing the risk of SCD in post-infarction patients is crucial to determining appropriate prevention strategies, such as implanting automatic implantable defibrillators (ICDs). Assessment tools are varied, but currently only left ventricular ejection fraction (LVEF) \\\u003C 35% is identified and validated. However, this risk stratification is unsatisfactory, particularly in view of SCD in patients with a history of myocardial infarction and a moderately impaired LVEF (between 35 and 50%). Although the initial treatment of myocardial infarction is essential for the patient's immediate survival, managing the risk of sudden death in the long term remains a major clinical challenge. A multiparametric approach is needed to optimize prognosis and prevent premature death in these patients.",[28,96],"Sudden Cardiac Death Due to Cardiac Arrhythmia",[98],"Sudden cardiac death in patients with ischemic heart disease and moderately impaired left ventricular ejection fraction (between 35 and 50%).","2026-06-12",{"date":74,"type":40},{"date":39,"type":21},{"date":103,"type":21},"2033-07-01",{"name":105,"class":47},"University Hospital, Clermont-Ferrand",10,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100595087","the-rule-out-acute-myocardial-infarction-using-aritifical-intelligence-electrocardiogram-romiae-2-trial-100595087","NCT07027891","The Rule-Out Acute Myocardial Infarction Using Aritifical Intelligence Electrocardiogram (ROMIAE) 2 Trial","ROMIAE 2 Trial: Randomized Controlled Trial for Managing Suspicious Acute Myocardial Infarction in ED Using AI-ECG","ROMIAE 2","Inclusion Criteria:\n\n* chest pain\n* suspicious of acute myocardial infarction\n\nExclusion Criteria:\n\n* STEMI\n* Revisit of same symptoms within 1 week\n* traumatic chest pain\n* Pneumothorax\n* Transferred from other hospital diagnosed of AMI\n* Cardiac arrest\n* Chest pain of clearly non-cardiac etiology\n* declined to participate in the study",{"count":116,"type":21},4670,[24],"This study is to see whether the AI ECG assisted protocol is as safe and efficacious as conventional protocol in early triage of suspected myocardial infarction.",[28,120],"Chest Pain Rule Out Myocardial Infarction",[122,123,124,125,126,127],"chest pain, suspicious myocardial infarction","artificial intelligence","electrocardiogram","emergency department","acute coronary syndrome","AI\u002FML-enabled SaMd","RECRUITING","2026-06-09",{"date":131,"type":40},"2026-06-11",{"date":133,"type":40},"2025-07-01",{"date":135,"type":21},"2028-02-28",{"name":137,"class":47},"CHA University",12,{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100583101","can-wearable-technology-be-used-to-predict-exercise-intensity-100583101","NCT06871943","Can Wearable Technology be Used to Predict Exercise Intensity","Developing a Rationale for the Use of Breathing Frequency and Wearable Foot-pods to Measure Intensity in Cardiac Populations","(CWTPEI)","Inclusion Criteria:\n\n* Myocardial Infraction in the past 6 months\n* Able to walk on a treadmill\n* Aged ≥ 18\n\nExclusion Criteria:\n\n• Injury or condition that impedes normal gait",{"count":148,"type":21},24,"OBSERVATIONAL","There is a knowledge gap in the literature around using watts to measure exercise intensity in walking and running, this is largely due to new technological developments. Whereas the relationship is widely recognised and used for cycling in elite to clinical populations.\n\nWhile the relationship breathing rate and exercise intensity is well established, this are no guidelines using breathing rate as a physiological measure of intensity. New technology may aid to bridge these gaps.\n\nThe main aims of the study are: -\n\nCan the relationship between oxygen uptake and watts during incremental exercise Can breathing frequency be used to determine aerobic exercise intensity\n\nThe participants will complete two 9 minute incremental accredited exercise tests on the flat around cones and on treadmill at the given speed of walking around the cones. The test will stop at 6.8kph or at participant volition.",[28],[153,154,155],"aerobic capacity","breathing frequency","walking capacity",{"date":157,"type":40},"2026-06-10",{"date":42,"type":21},{"date":160,"type":21},"2027-06-30",{"name":162,"class":47},"Keele University",{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":173,"studyType":149,"phases":4,"briefSummary":174,"conditions":175,"keywords":182,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":48},"100643069","beat-shock-registry-100643069","NCT07643610","BEAT-SHOCK Registry","BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry","BEAT-SHOCK","* Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay\n* Age ≥18 years\n* Provision of written ICF\n* Clinical diagnosis of cardiogenic shock.\n* impaired organ perfusion due to primary cardiac dysfunction,\n* persistent systolic blood pressure (SBP) \\\u003C90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and\n* evidence of systemic hypoperfusion with arterial lactate ≥2 mmol\u002FL or venous lactate ≥3 mmol\u002Fl and ≥1 of the following:\n* Cold or clammy extremities\n* Altered mental status\n* Reduced urine output\n* Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring)\n* Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol\u002FL or venous lactate ≥3 mmol\u002Fl) and cardiac dysfunction are present and alternative causes are excluded\n\nExclusion criteria:\n\n* Age \\\u003C18 years\n* Refusal to provide informed consent by the patient or their legally authorized representative",{"count":172,"type":21},8000,"5 Years","This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.",[176,28,177,178,179,180,181],"Cardiogenic Shock","Fulminant Myocarditis","Acute Decompensated Heart Failure","Severe Valvular Disease","Post-cardiotomy","Perioperative Cardiogenic Shock",[183,184,185,186,187,188,189],"cardiogenic shock","Myocardial infarction (MI)","Fulminant myocarditis","Acute decompensated heart failure","Severe valvular disease","Post-cardiotomy or perioperative cardiogenic shock","wide range of cardiogenic shock etiologies","2026-06-08",{"date":131,"type":40},{"date":193,"type":40},"2025-10-01",{"date":195,"type":21},"2035-10-01",{"name":197,"class":47},"University Hospital, Basel, Switzerland",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100638546","low-dose-interleukin-2-after-myocardial-infarction-to-investigate-effects-on-tissue-resident-regulatory-t-cells-100638546","NCT07610538","Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells","Leuk-ALIVE","Inclusion Criteria:\n\n* Aged over 18 years old\n* Undergoing CABG surgery\n\nExclusion Criteria:\n\n* Critical left main stem coronary disease\n* Severe valvular disease (for example 'severe' aortic stenosis as classified on echocardiogram report)\n* Haemodynamic instability caused by arrhythmia requiring cardioversion in the current admission\n* Non-sustained ventricular tachycardia of \\>10 beats in the last 48 hours\n* Autoimmune disease\n* Any regular immunosuppressive treatment \\[Inhaled or topical steroids are permissible\\]\n* Known active hepatic disease or alanine aminotransferase (ALT) \\> 3xULN\n* Severe chronic kidney disease (defined as eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2)\n* Allergy or intolerance to aldesleukin\n* Signs and symptoms of active infection\n* History of human immunodeficiency virus (HIV), hepatitis B or C\n* Current malignancy requiring active treatment\n* Vaccine within 4 weeks prior to screening\n* Women of child-bearing potential and pregnancy (women must be either postmenopausal (defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile (e.g. age appropriate (\\>55 years old), history of vasomotor symptoms) or having documented hysterectomy and\u002For bilateral oophorectomy)\n* Women who are breast-feeding\n* Clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study",{"count":148,"type":21},[24],"The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell\u002F-nucleus RNA sequencing in patients treated with ld-IL-2 compared to control grouped by individual tissue beds from in and around the heart. Additionally, tissue-resident Tregs will be compared to peripheral blood Tregs from the same patient to assess the differential effect of ld-IL-2 on the two compartments.",[29,28,209],"CABG",[211,212,213,68,209,214],"Interleukin-2","IL-2","MI","Coronary artery bypass graft","2026-05-20",{"date":217,"type":40},"2026-05-28",{"date":219,"type":40},"2026-03-31",{"date":221,"type":21},"2028-12-01",{"name":223,"class":47},"Cambridge University Hospitals NHS Foundation Trust",2,{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":48},"100598866","ticino-artificial-intelligence-integration-for-occlusion-myocardial-infarction-100598866","NCT07077057","Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction","TITAN-OMI","Inclusion Criteria:\n\n1. Symptoms suspected of ongoing acute myocardial ischemia: Patients presenting with symptoms such as chest pain, dyspnoea, sweating, nausea or vomiting, pain radiating to the shoulder\u002Farm\u002Fjaw\u002Fback, fatigue, or light-headedness\n2. Age: Patients aged 18 years or older.\n3. Informed Consent: Patients able to provide informed consent\n\nExclusion Criteria:\n\n1. Clear diagnosis of ST-segment elevation MI (STEMI) according to managing physicians.\n2. Pregnancy or Lactation.\n3. Legally incompetent to provide informed consent.\n4. Symptoms onset\\>24 hrs prior to clinical presentation.",{"count":233,"type":21},500,[24],"The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with suspected acute coronary syndrome (ACS) who do not meet traditional ST-elevation myocardial infarction (STEMI) criteria.\n\nThe main questions it aims to answer are:\n\n1. Does AI-assisted ECG interpretation enable more timely identification and treatment of OMI, as defined by earlier initiation of coronary intervention?\n2. Does AI-assisted diagnosis reduce infarct size, measured by peak high-sensitivity troponin T (hsTnT) levels?\n\nResearchers will compare AI-assisted ECG interpretation to standard care to determine if the AI tool improves clinical outcomes and care timelines.\n\nParticipants will:\n\n1. Present with symptoms suggestive of ACS but without clear STEMI criteria\n2. Be randomized 1:1 to either AI-assisted or standard ECG interpretation\n3. Undergo follow-up assessments for cardiovascular outcomes, including 30-day death, time to treatment of total coronary occlusion, and peak hsTnT levels",[28,237],"Acute Coronary Syndrome (ACS)",[239,240,241],"Occlusion Myocardial Infarction","Electrocardiogram","Artificial Intelligence","2026-04-29",{"date":244,"type":40},"2026-05-05",{"date":246,"type":40},"2025-08-23",{"date":248,"type":21},"2027-09",{"name":250,"class":47},"Cardiocentro Ticino",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":4},"100636308","prehospital-point-of-care-hs-troponin-i-for-rule-out-of-acute-myocardial-infarction-in-patients-without-st-segment-elevation-100636308","NCT07563998","Prehospital Point-of-Care Hs-Troponin I for Rule-Out of Acute Myocardial Infarction in Patients Without ST-Segment Elevation","Prehospital Point-of-Care High-Sensitivity Troponin I for Rule-Out of Acute Myocardial Infarction in Suspected Non-ST-Segment Elevation Acute Coronary Syndrome: A Pilot Study","Pre-POCT TnI","Inclusion Criteria:\n\n* Age 18 years or older\n* Assessed by one of the participating EMS units equipped for POCT sampling\n* Presentation with symptoms suggestive of acute coronary syndrome\n* Planned transport to hospital for further evaluation\n\nExclusion Criteria:\n\n* ST-segment elevation on prehospital electrocardiogram\n* Clinical condition requiring immediate life-saving intervention precluding study procedures\n* Interhospital transport\n* Prior inclusion in the study within 30 days",{"count":233,"type":21},"People who call emergency medical services (EMS) with chest pain or other possible heart-related symptoms are often taken to hospital for further testing. However, only a small proportion of these patients are ultimately diagnosed with a serious heart condition such as a heart attack. This means that many patients undergo hospital transport and evaluation even though their risk is low.\n\nIn hospitals, a blood test called high-sensitivity cardiac troponin is commonly used to help diagnose or rule out heart attacks. It is not yet well established whether this type of test can be used safely and effectively earlier, in the prehospital setting.\n\nThis study will investigate whether it is feasible to measure high-sensitivity troponin in the ambulance and how well the test can identify patients at low risk of serious heart conditions. A small blood sample will be taken as part of routine care and analyzed using a portable device. The test result will not be used to guide treatment or decisions during the study.\n\nThe study will assess how well the test predicts heart-related events within 30 days and how practical it is to perform the test in real-life emergency settings. The results may help guide future research on how to improve early assessment and decision-making for patients with suspected heart disease.",[28,262],"Acute Coronary Syndromes (ACS)",[264,265,266,267,268,269,270,271,272,273,274],"Prehospital","Emergency Medical Services","Point-of-Care Testing","POCT","High-Sensitivity Troponin I","Chest Pain","Non-ST Elevation","Diagnostic Accuracy","Risk Stratification","Major Adverse Cardiac Events","MACE","2026-04-26",{"date":277,"type":40},"2026-05-04",{"date":279,"type":21},"2026-05-15",{"date":160,"type":21},{"name":282,"class":47},"Central Denmark Region",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":48},"100570105","gsi-cardiac-on-revolution-apex---us-100570105","NCT06702917","GSI Cardiac on Revolution Apex - US","Wide Coverage GSI Cardiac Data Collection","Inclusion Criteria:\n\nSubjects may be included in this study if they meet the following criteria:\n\n1. Who are ≥18 years of age;\n2. Able to sign and date the informed consent form; AND,\n3. Cohort A: Undergoing a scheduled clinically indicated CCTA; OR,\n4. Cohort B: Known history of myocardial infarction or undergoing a clinically indicated cardiac catheterization due to known pathology.\n\nExclusion Criteria:\n\nSubjects may be excluded from participating in study if they meet any of the following criteria:\n\n1. Who are pregnant or lactating;\n2. Who were previously enrolled in this study;\n3. Anyone with known or suspected allergy to iodinated contrast agents;\n4. Anyone with known or suspected renal insufficiency as determined by site medical personnel;\n5. Who are in need of urgent or emergent care;\n6. Who have any conditions that, in the opinion of the PI or designee, would interfere with the evaluation of the results or constitute a health hazard for the subject;\n7. Who are unwilling to have GEHC personnel present for the CT exam; AND,\n8. Cohort A: Undergoing a scheduled clinically indicated CCTA for anatomy assessment (aberrant origin, etc.)",{"count":291,"type":21},50,"The goal of this clinical data collection study is to collect raw CT scan data using a new GSI Cardiac mode on GE HealthCare's Revolution Apex CT system.\n\nTwo groups of participants will be enrolled:\n\nA) Participants scheduled to undergo a Coronary CT Angiography (CCTA) as part of their standard of care\n\nB) Participants scheduled to undergo a cardiac catheterization or have a history of heart attack\n\nParticipants in Group A will:\n\n-Have a standard of care CCTA immediately followed by a research GSI Cardiac scan\n\nParticipants in Group B will:\n\n-Have a research CCTA immediately followed by a research GSI Cardiac scan\n\nBoth groups will be in the study for approximately 1 day. There are no follow-up visits after the day of scan.",[294,28,295],"Coronary Computed Tomographic Angiography","Cardiac Catheterization","2026-04-24",{"date":298,"type":40},"2026-04-27",{"date":300,"type":40},"2025-09-10",{"date":302,"type":21},"2026-06",{"name":304,"class":305},"GE Healthcare","INDUSTRY",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":48},"100610643","telegram-messenger-support-for-smoking-cessation-after-heart-attack-100610643","NCT07230249","Telegram Messenger Support for Smoking Cessation After Heart Attack","Effect of a Behavioral Intervention Delivered Via Telegram Messenger on Smoking Cessation in Patients After Myocardial Infarction: The TELEGRAM-MI Randomized Controlled Trial","TELEGRAM-MI","Inclusion Criteria:\n\n* Willing and able to provide written informed consent.\n* Age 18 years or older.\n* Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI).\n* Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization.\n* Regular user of the Telegram messenger application (app installed on a personal smartphone).\n* Possession of a smartphone with internet access and a valid phone number.\n* Ability and willingness to provide contact information for a close relative or cohabiting person who can verify smoking status at follow-up.\n\nExclusion Criteria:\n\n* Smoking cessation more than 1 month prior to the index MI hospitalization.\n* Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual\u002Fhearing impairment, inability to read or respond to messages).\n* Inability to read and understand the Russian language fluently.\n* Comorbid condition with a life expectancy of less than 1 year.\n* Active severe mental illness (e.g., psychosis, severe untreated depression) that would impede understanding of the protocol or adherence.\n* Unwillingness or inability to provide contact details for a close relative for outcome verification.",{"count":315,"type":21},142,[24],"This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI).\n\nAdult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either:\n\n* INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support.\n* CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content.\n\nThe primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics.\n\nThis study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.",[28,319,320],"Tobacco Use","Smoking Cessation",[322,323,324,325,326,327,328],"Telegram","Chatbot","Digital Health","Behavioral Intervention","Secondary Prevention","Randomized Controlled Trial","Cardiac Rehabilitation","2026-04-02",{"date":331,"type":40},"2026-04-03",{"date":333,"type":21},"2026-05-01",{"date":335,"type":21},"2027-01-01",{"name":337,"class":47},"ITMO University",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":22,"phases":348,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":368},"100631962","phase-4-dual-antiplatelet-therapy-strategies-after-acute-myocardial-infarction-undergoing-pci-prasugrel-vs-ticagrelor--12-months-vs-1-3-months-100631962","NCT07507500","Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months","Strategies for Antiplatelet Management Following Acute Coronary Syndrome","STREAMLINE","Inclusion Criteria:\n\n* ≥18 years old\n* Admitted because of an acute MI (either STEMI or NSTEMI).\n* Invasive management during index admission with successful PCI.\n* Able to consent.\n\nExclusion Criteria:\n\n* Indication for oral anticoagulation therapy.\n* Intolerance, contraindication or known allergy to either aspirin, prasugrel or ticagrelor.\n* Prior history of ischaemic or haemorrhagic stroke or transient ischaemic attack.\n* Patients with active bleeding or known bleeding disorders.\n* Patients with known moderate or severe hepatic dysfunction (Child-Pugh Class B or Class C).\n* Known intracranial aneurism, arteriovenous malformation or neoplasm.\n* Patients with chronic kidney disease requiring dialysis.\n* Any disorder that may interfere with drug absorption.\n* Pregnancy or current lactation.\n* Concomitant use of potent CYP3A inhibitors or inducers.\n* Planned elective surgery that cannot be deferred 12 months before randomization, requiring interruption of antiplatelet therapy.\n* Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year)\n* Active participation in other clinical trials.",{"count":347,"type":21},8100,[349],"PHASE4","This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one.\n\nAfter PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding.\n\nThis study is not testing any new intervention, rather comparing approved drugs and approved durations of use.",[28],[126,353,354,355,356,357,358,359],"infarction","DAPT","dual antiplatelet therapy","prasugrel","ticagrelor","ischemic event","bleeding","2026-03-27",{"date":329,"type":40},{"date":363,"type":21},"2026-07",{"date":365,"type":21},"2030-01",{"name":367,"class":47},"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz",5,{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":22,"phases":379,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":395},"100593109","timing-of-coronary-angiography-in-nstemi-complicated-by-acute-hf-100593109","NCT07002164","Timing of Coronary Angiography in NSTEMI Complicated by Acute HF","Trial of IMmediate Invasive Versus Delayed Coronary ANGiography in Non-ST-Segment Elevation Myocardial Infarction Complicated by Acute Decompensated Heart Failure: The TIMING-AHF Trial","TIMING-AHF","Inclusion Criteria:\n\n* Age ≥19 years\n* Non-ST-segment elevation myocardial infarction\n* New-onset or worsening of dyspnea (New York Heart Association class ≥2)\n* Pulmonary congestion\n* Patient's or guardian's consent after understanding the study\n\nExclusion Criteria:\n\n* Cardiogenic shock at initial presentation\n* ST-segment elevation myocardial infarction\n\n  * ST-segment elevation ≥0.1 mV in at least 2 contiguous leads, or\n  * New onset left bundle branch block\n  * Posterior wall myocardial infarction\n* Refractory angina\n* Life threatening ventricular arrhythmias\n* Life expectancy \\\u003C1 year\n* Apparently non-ischemic cause of HF\n* Pregnancy and lactation\n* History of coronary artery bypass grafting (CABG), or planned CABG\n* Patient's refusal to participate in study",{"count":378,"type":21},780,[24],"Study objectives:\n\nTo determine the optimal timing of coronary angiography (CAG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by acute decompensated heart failure (AHF). The primary objective of this trial is to test the hypothesis that immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.\n\nStudy hypothesis:\n\nImmediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.\n\nBackground:\n\nAlthough current guidelines recommend early CAG within 2 hours for patients with NSTEMI complicated by AHF, many patients with NSTEMI complicated by AHF did not receive early CAG. However, no randomized clinical trials have evaluated the optimal timing of CAG in patients with NSTEMI complicated by AHF. Therefore, the investigators aimed to perform a prospective, investigator-initiated, open-label, muilticenter trial to compare the efficacy and safety between immediate CAG (CAG \\\u003C2 hours after establishment of NSTEMI diagnosis) and delayed CAG after stabilization (i.e. improved dyspnea and disappearance of pulmonary congestion) in participants with NSTEMI complicated by AHF.\n\nStudy procedure:\n\nFollowing the establishment of NSTEMI diagnosis, participants fulfilling the eligibility criteria will be randomized at a ratio of 1:1 to immediate CAG ≤2 hours after randomization or delayed CAG after stabilization on another day during hospitalization.",[28,382],"Heart Failure",[384,186,385,386],"Non-ST-segment elevation myocardial infarction","Coronary angiography","Timing","2026-03-17",{"date":389,"type":40},"2026-03-19",{"date":391,"type":40},"2025-07-15",{"date":393,"type":21},"2032-04-30",{"name":81,"class":47},20,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":407,"conditions":408,"keywords":411,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":48},"100597001","phase-3-aspirin-continuation-or-interruption-in-patients-at-moderate-risk-for-cardiovascular-events-undergoing-colonoscopy-andor-polypectomy-100597001","NCT07052799","Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and\u002For Polypectomy","Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and\u002For Polypectomy; a Placebo-controlled Trial","Inclusion Criteria:\n\n* patients receiving aspirin (80mg daily or more) for secondary prevention against cardiovascular diseases who require elective colonoscopy for colorectal cancer screening.\n\nExclusion Criteria:\n\n* patients who received a coronary stent of any type within 6 months\n* patients who had a cardiovascular event within 3 months\n* patients who had concurrent use of anticoagulants (warfarin or NOAC) or other antiplatelet drugs (P2Y12 receptor antagonists)\n* patient with bleeding diathesis e.g., hemophilia, von Willebrand's disease or coagulopathy from liver cirrhosis\n* patient with terminal malignancies or medical illnesses.\n* patient who is unable or refuse to give consents",{"count":404,"type":21},2514,[406],"PHASE3","One in 4 adults between 50 and 80 reports taking regular aspirin. The prevalence of aspirin uses increases with age as well as co-morbid vascular diseases. Patients with cardiovascular diseases are at risk of developing colorectal neoplasms. In patients undergoing screening colonoscopy, interruption of aspirin is believed to be associated with increased cardiovascular events. Continuation of aspirin can however be associated with an increased risk of post-polypectomy bleeding. International guidelines on periendoscopy management recommend the continuation of aspirin based on evidence from cohort studies, mostly retrospective, suggesting that the rate of bleeding is low. Cardiovascular complications from aspirin interruption can lead to disabilities and occasional deaths. The cardiovascular risks following aspirin continuation or interruption in endoscopy have not been well studied. There has been no randomized study to compare either strategy. Endoscopists are divided on their opinion on whether to stop or to continue aspirin. The proposed large randomized controlled trial (RCT) is powered to detect small differences in both outcomes. Findings from this RCT will address this important question and inform our clinical practice.",[28,409,410],"Cardiovascular Events","Post Polypectomy Bleeding in Antiplatelet Patients",[412,413,414],"Aspirin continuation or interruption","polypectomy","cardiovascular events","2026-03-16",{"date":417,"type":40},"2026-03-18",{"date":419,"type":40},"2026-02-10",{"date":421,"type":21},"2031-12-31",{"name":423,"class":47},"Chinese University of Hong Kong",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":432,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":48},"100629076","the-effect-of-sodium-glucose-co-trnasportert-type-2-inhibitors-on-arterial-stiffness-endothelial-glycocalyx-thickness-and-cardiac-deformation-after-acute-myocardial-infarction-100629076","NCT07469943","The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness and Cardiac Deformation After Acute Myocardial Infarction","The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness , Left Atrial and Left Ventricular Deformation After Acute Myocardial Infarction","SGLT2i-MI-glyc","Inclusion Criteria:\n\n* STEMI participants with type 2 diabetes or LVEF\\\u003C40%\n\nExclusion Criteria:\n\n1. Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73 m²\n2. Active malignancy\n3. Autoimmune or autoinflammatory disorders\n4. Severe hepatic impairment\n5. Pregnancy or breastfeeding",{"count":433,"type":21},80,"Acute myocardial infarction (MI) remains one of the leading causes of cardiovascular morbidity and mortality worldwide. It most commonly occurs due to acute coronary artery occlusion following rupture or erosion of an atherosclerotic plaque and subsequent thrombus formation. Despite significant advances in reperfusion strategies and guideline-directed pharmacological therapy, patients who survive MI remain at increased risk for adverse cardiovascular outcomes, including heart failure, recurrent myocardial infarction, stroke, and cardiovascular death. Therefore, additional therapeutic strategies that may improve vascular function, myocardial remodeling, and overall cardiovascular prognosis following MI are of considerable clinical interest.\n\nSodium-glucose cotransporter-2 (SGLT2) inhibitors have recently emerged as an important pharmacological class with significant cardiometabolic benefits. Large randomized clinical trials have demonstrated that SGLT2 inhibitors reduce the risk of hospitalization for heart failure and cardiovascular mortality in patients with type 2 diabetes mellitus and in patients with heart failure irrespective of diabetic status. The cardioprotective effects of these agents appear to extend beyond glycemic control and include improvements in myocardial energetics, vascular function, inflammation, and oxidative stress. Emerging evidence suggests that SGLT2 inhibitors may also exert beneficial effects on vascular stiffness, endothelial function, and myocardial remodeling. However, data regarding their potential impact on arterial stiffness, endothelial glycocalyx integrity, and myocardial deformation parameters in the early post-myocardial infarction setting remain limited.\n\nThe primary aim of the present study is to investigate the effect of empagliflozin administration (10 mg daily) on arterial stiffness, endothelial glycocalyx thickness, and myocardial deformation indices of the left ventricle and left atrium during a 12-month follow-up period in patients presenting with ST-segment elevation myocardial infarction (STEMI).\n\nSecondary objectives include:\n\n1. evaluation of the incidence of major adverse cardiovascular events (MACE), defined as cardiovascular death, recurrent myocardial infarction, and acute ischemic stroke;\n2. investigation of the association between the occurrence of MACE and vascular and myocardial functional parameters, including indices of arterial stiffness, endothelial glycocalyx integrity, and myocardial strain measurements; and\n3. assessment of oxidative stress burden through circulating biomarkers. This prospective observational study will include adult patients diagnosed with acute STEMI who are hospitalized in the Second University Cardiology Clinic of \"Attikon\" General Hospital. All participants will provide written informed consent prior to enrollment and will receive standard guideline-directed therapy for acute myocardial infarction according to the current European Society of Cardiology (ESC) guidelines.\n\nParticipants will be allocated into two groups. Group A will include patients receiving empagliflozin 10 mg once daily, initiated either at hospital discharge in patients with concomitant type 2 diabetes mellitus or in patients without diabetes who present with reduced left ventricular ejection fraction (LVEF \\\u003C40%). Group B will serve as the control group and will not receive empagliflozin therapy. The anticipated sample size of the study is 80 patients, with approximately 40 participants in each group.\n\nExclusion criteria include chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73 m², active malignancy, autoimmune or autoinflammatory disorders, severe hepatic impairment, and pregnancy or breastfeeding.\n\nParticipants will undergo detailed evaluation at baseline and at 3, 6, and 12 months. Arterial stiffness will be assessed through measurement of carotid-femoral pulse wave velocity (cf-PWV) using the Complior SP system, which represents the gold standard non-invasive method for evaluating large-artery stiffness. In addition, 24-hour pulse wave analysis will be performed using the Mobil-O-Graph device to obtain central hemodynamic parameters.\n\nEndothelial function will be evaluated through assessment of endothelial glycocalyx thickness in sublingual microvessels using Sidestream Dark Field (SDF) imaging with the GlycoCheck system. Glycocalyx integrity will be quantified by the Perfused Boundary Region (PBR) index, which reflects erythrocyte penetration into the glycocalyx layer and serves as a marker of endothelial barrier dysfunction.\n\nCardiac structure and function will be assessed using two-dimensional speckle-tracking echocardiography. Global longitudinal strain (GLS) of the left ventricle will be calculated using the standard 17-segment model from apical views, while left atrial strain will be measured to evaluate atrial reservoir and contractile function, providing sensitive markers of myocardial remodeling after infarction",[28,436],"Diabete Type 2",[438,439,440,441],"arterial stiffness","sglt2i","myocardial deformation","endothelial glycocalyx","2026-03-10",{"date":444,"type":40},"2026-03-13",{"date":446,"type":40},"2026-01-09",{"date":448,"type":21},"2028-12-20",{"name":450,"class":47},"University of Athens",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":461,"studyType":149,"phases":4,"briefSummary":462,"conditions":463,"keywords":467,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":483,"locationsCount":48},"100626499","drug-coated-balloon-primary-pci-in-st-segment-elevation-myocardial-infarction-100626499","NCT07436429","Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction","Drug Coated Balloon-Based Primary PCI in ST-segment Elevation Myocardial Infarction - The DCB-STEMI Multicenter Registry","DCB-STEMI","Inclusion Criteria:\n\n* All ST-elevation MI undergoing Primary PCI\n\nExclusion Criteria:\n\n* In-stent culprit lesion\n* Contraindications to antiplatelets\n* Stent implantation within 3 months before enrollment\n* Cardiac arrest, intubation, or cardiogenic shock\n* Life-expectancy less than one year",{"count":460,"type":21},300,"30 Days","Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomical and clinical settings, including de novo coronary lesions. A DCB-based pPCI strategy may simplify the procedure and mitigate the risks of inadequate stent sizing due to spasm or large thrombus burden, acute stent thrombosis, distal embolization, no reflow, and the relatively higher incidence of late stent-related adverse events compared with elective PCI. Despite these theoretical advantages, data on the safety and efficacy of DCB-based pPCI in STEMI remains limited.\n\nThe aim of this registry is to explore procedural and clinical outcomes of patients with STEMI treated with a DCB-based pPCI strategy.",[28,464,69,465,466],"ST-Elevation Myocardial Infarction","STEMI (STE-ACS)","Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)",[468,469,470,471,472,473,474,475,476],"Drug-coated balloon","Primary percutaneous coronary intervention","De novo coronary lesion","Limus-coated balloon","Paclitaxel-coated balloon","Net adverse clinical events","Bleeding Academic Research Consortium bleeding","ST-segment elevation myocardial infarction","Drug-Eluting Balloon","2026-02-22",{"date":479,"type":40},"2026-02-27",{"date":481,"type":40},"2026-02-08",{"date":39,"type":21},{"name":484,"class":47},"Medical University of Vienna",{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":17,"minAge":493,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":22,"phases":496,"briefSummary":497,"conditions":498,"keywords":505,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":48},"100575341","community-physical-exercise-program-in-chronic-disease-100575341","NCT06771024","Community Physical Exercise Program in Chronic Disease","Effectiveness of Community Physical Exercise Program in Chronic Disease (CPEP - Chronic Disease), a Clinical Randomized Controlled Trial","CPEPCD","Inclusion Criteria:\n\n* Adults aged ≥50 years;\n* At least 2 of the following: Prior cardiovascular disease (\\>12 months); High cardiovascular risk (SCORE2 or SCORE2 O.P.); Post-stroke (ischemic or hemorrhagic) with treated etiology; Type 2 Diabetes (\\> 6 months, ADA); Osteoarthristis (clinical signs\u002Fsymptoms, NICE); Overweight\u002FObesity (BMI ≥ 27 kg\u002Fm2).\n* Autonomous walking.\n* Able to provide informed consent.\n* Stable medications for ≥ 3 months (related to diagnoses of interest).\n* Physical activity below WHO recommendations.\n* No contraindications to exercise (cardiovascular, cerebrovascular, respiratory, musculoskeletal) according to ACSS.\n\nExclusion Criteria:\n\n* Moderate to severe cognitive impairment - Montreal Cognitive Assessment (MoCA).\n* Type 2 Myocardial Infarction.\n* Class III or IV angina (Canadian Cardiovascular Society).\n* Class III or IV angina (New York Heart Association).\n* Uncontrolled CVD: symptomatic arrhythmias with hemodynamic compromise; severe symptomatic aortic valve stenosis; uncontrolled symptomatic heart failure; endocarditis, pericarditis, or active myocarditis; acute aortic syndrome; suspected or known dissecting aneurysm; acute systemic infections.\n* Pacemaker user.\n* Neurological disorders affecting gait.\n* Severe diabetes-related complications contraindicating exercise (poor metabolic control, diabetic foot, diabetic retinopathy, diabetic nephropathy, and diabetic autonomic neuropathy).\n* Recent use of insulin or sulphonylureas (\\\u003C 3 months).\n* Untreated stroke etiology: indication for revascularization; non-anticoagulated atrial fibrillation; intracranial atherosclerotic occlusive disease.\n* Musculoskeletal or ocular conditions preventing strength training (acute herniated disc, fractures, recent spinal surgery, glaucoma with elevated intraocular pressure).\n* Terminal illness.\n* Inability to understand basic oral or written Portuguese.\n* Participation in supervised dietary intervention.","50 Years",{"count":495,"type":21},150,[24],"This study focuses on promoting physical activity (PA) through the implementation of a Community Physical Exercise Program for Chronic Diseases (CPEP-CD), targeting individuals aged 50 years and older with at least two of the following conditions: cardiovascular and\u002For cerebrovascular disease or risk (CVD), overweight, diabetes mellitus (DM), and musculoskeletal diseases. The primary objective is to improve muscle and cardiorespiratory health and well-being, while also contributing to a more objective and evidence-based exercise prescription for these pathological conditions.\n\nPopulation ageing is a global challenge associated with an increased prevalence of chronic diseases that compromise quality of life (QoL). A sedentary lifestyle is linked to declines in muscle function and cardiorespiratory fitness and is considered a major risk factor for morbidity and mortality. Consequently, physical exercise is widely recommended as a key non-pharmacological intervention across multiple chronic diseases.\n\nAccording to World Health Organization (WHO) guidelines, regular PA is a protective factor in the prevention and management of non-communicable diseases, including cardiovascular and cerebrovascular diseases and DM. In addition, PA provides mental health benefits, supports healthy weight maintenance, and enhances overall well-being. In adults, regular PA is associated with reductions in all-cause mortality, cardiovascular mortality, and the incidence of hypertension.\n\nWithin this context, the aim of this project is to implement a community-based physical exercise program for individuals with chronic disease and multimorbidity, focusing on CVD and cerebrovascular disease or risk, DM, and OA. The program integrates existing exercise prescription guidelines while personalizing exercise progression according to both disease-specific and multimorbidity profiles. The primary outcomes include improvements in cardiorespiratory fitness, muscular strength, bone health, functional capacity, and QoL. Additionally, through individualized training monitoring, this study seeks to establish an exercise prescription tailored to the most prevalent combinations of chronic diseases, thereby providing more objective and practical guidance for family physicians, exercise professionals, and rehabilitation specialists, and supporting more personalized and targeted exercise-based strategies for chronic disease prevention and management.",[499,28,500,501,502,503,504],"Osteoarthritis Pain","Hypertension","Dyslipidemia","Diabetes Mellitus","Overweight , Obesity","Stroke",[506,507,508,509,510,511,502,512],"Physical Exercise Program","Healthy Ageing","Cardiovascular Risk","Osteoarthritis","Multimorbility","Chronic Diseases","Cerebrovascular risk","2026-02-04",{"date":515,"type":40},"2026-02-06",{"date":517,"type":21},"2026-05",{"date":519,"type":21},"2026-12",{"name":521,"class":522},"Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv","NETWORK",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":22,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":48},"100622801","diagnostic-accuracy-of-ecg-less-gated-cardiac-ct-in-resuscitated-cardiac-arrest-survivors-without-st-elevation-myocardial-infarction-100622801","NCT07388342","Diagnostic Accuracy of ECG-less Gated Cardiac CT in Resuscitated Cardiac Arrest Survivors Without ST Elevation Myocardial Infarction","Diagnostic Accuracy of ECG-less Gated Cardiac CT in Resuscitated Cardiac Arrest Survivors","OPEN CCTArrest","* Inclusion:\n\n  * Adults (≥18 years) with sustained return of spontaneous circulation (ROSC) following in\u002Fout-of-hospital cardiac arrest.\n  * Informed consent from patient or representative obtained before invasive coronary angiography.\n* Exclusion\n\n  * Patients on VA-ECMO\n  * ACS STEMI or STEMI \"equivalent\"\n\n    * New left\u002Fright bundle branch block\n    * ST segment depression in leads V1-V3, when the terminal T wave is positive and concomitant ST-segment elevation ≥ 0,5mm recorded in leads V7-V9 (posterior MI)\n    * ST-segment elevation in V7-V9 (posterior MI) or V3R-V4R (RV MI)\n  * ACS NSTEMI with persistent ST depression despite optimal therapy, suggesting ongoing myocardial ischemia, with indication for an urgent ICA according to the treating physician.\n  * Hemodynamic\u002Felectrical instability precluding CT imaging (as perceived by the treating physician)\n  * Life-threatening arrhythmia potentially caused by acute myocardial ischemia\n  * Absolute contraindications to iodinated contrast\n  * Patients with a known non-cardiac cause of cardiac arrest (e.g., traumatic brain injury, overt hemorrhage, asphyxia\u002Fsevere hypoxia due to known lung disease, trauma, severe metabolic\u002Felectrolyte derangement, or intoxication) as perceived by the treating physician, where chest CT is considered unnecessary.\n  * Known or likely pregnancy or lactation\n  * Severe bleeding issue (as perceived by the treating physician) precluding heparin administration during radial access coronary angiography.\n  * Prior coronary intervention (stent implantation\u002FCABG).\n  * CT findings indicating a condition that precludes coronary angiography in the short term.\n  * Patients with end-of-life care pathways.\n  * Participation in another intervention study interfering with the research questions in OPEN CCT Arrest.",{"count":532,"type":21},30,[24],"In a significant portion of patients surviving a cardiac arrest, the event is caused by a myocardial infarction (a narrowing or blockage of one or more blood vessels that supply blood to the heart, the coronary arteries). In some people, this is immediately evident from basic tests; in others, it is more difficult to predict with the currently available tests whether this (or something else) caused the cardiac arrest. We investigate a technique that allows us to also assess the coronary arteries on the CT scan that is performed in patients surviving a cardiac arrest. The coronary angiography is currently the best exam we have for examining the coronary arteries, but it has some disadvantages. Compared to the CT scan, it takes more time, needs a more complex access to the blood vessels, and has some rare but relevant possible complications. The major advantage of the coronary angiography is that there is the possibility of immediate treatment of a narrowed\u002Fblocked blood vessel of the heart. The current guidelines advice an urgent coronary angiography when a clear myocardial infarction is suggested on the electrocardiogram, but not when there is no clear indication of myocardial infarction. Nonetheless, a relevant portion (more or less 40%) of the patients without a clearly abnormal electrocardiogram, still have an important problem in the blood vessels of the heart. We aim to determine whether the CT scan provides accurate information about the condition of the blood vessels of the heart. The CT scan was already well examined for this purpose before, but in the currently conventional way it needs preparation with extra monitoring and administration of medication, which would lead to loss of precious time and potentially dangerous side effects of these drugs in this critical situation. For that reason, a new software modality was developed that allows us to examine the coronary arteries in the same CT scan, without need for additional monitoring or medication administration. It does not need additional contrast administration (the dye necessary for optimal evaluation of some diseases).\n\nThe goal of this study is to determine whether this new technique gives us the correct information about the coronary arteries. This means we acquire the images of the heart in the same scan, and verify the results with the conventional coronary angiography. If the technique provides accurate information, it could lead to a better selection of patients we need to urgently refer for a coronary angiography and to defer the exam in those who have normal coronary arteries on the scan.",[536,28],"Cardiac Arrest (CA)",[538,539,540],"Cardiac Arrest","Myocardial Infarction","Coronary Computed Tomography Angiography (CCTA)","2026-01-29",{"date":543,"type":40},"2026-02-05",{"date":545,"type":40},"2025-09-01",{"date":547,"type":21},"2027-12-01",{"name":549,"class":47},"Universitair Ziekenhuis Brussel",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":560,"conditions":561,"keywords":567,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":48},"100620203","prognosis-of-patients-with-mixed-cardiogenic-vasoplegic-shock-100620203","NCT07354568","Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock","Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock: a French Multicenter Cohort","PROMIX","Inclusion Criteria:\n\n* Adult patient (\\>18 years old)\n* Admitted to an intensive care unit for cardiogenic shock, at least SCAI stage C\n* No opposition to data use\n\nExclusion Criteria:\n\n* Missing key data, particularly regarding vasopressor doses and outcomes.\n* Pregnant women\n* Non-eligible shock etiologies, including but not limited to:\n* Anaphylactic shock,\n* Isolated hemorrhagic shock,\n* Severe burns or major trauma,\n* Severe acute pancreatitis,\n* Fulminant hepatic failure,\n* Neurogenic shock.\n* Adult under legal protection (guardianship, curatorship, or judicial protection).",{"count":559,"type":21},2500,"Mixed cardiogenic-vasoplegic shock (M-CS) represents a distinct and severe phenotype of cardiogenic shock characterized by concomitant myocardial dysfunction and inappropriate systemic vasodilation. Despite its clinical relevance, the epidemiology, management, and outcomes of M-CS remain poorly defined.\n\nThis retrospective, multicenter, observational registry aims to evaluate the clinical outcomes and prognostic factors associated with mixed cardiogenic-vasoplegic shock. The study will analyze clinical, biological, and invasive hemodynamic data routinely collected during patient management for M-CS.\n\nAll included patients will have been admitted for cardiogenic shock, with or without vasoplegia, defined by low cardiac output and, when present, decreased systemic vascular resistance despite adequate filling pressures requiring vasopressor support.\n\nThe primary objective is to describe mortality and organ failure rates, while secondary analyses will identify determinants of adverse outcomes and potential phenotypic subgroups.\n\nThe PROMIX registry will be conducted across three French university hospitals (CHU Amiens-Picardie, CHU Dijon-Bourgogne, and CHU Rouen-Normandie).\n\nThis study is non-interventional, involving only data obtained as part of routine critical care, and will provide the first multicenter overview of this complex and underrecognized form of cardiogenic shock.",[562,563,564,565,28,566],"Cardiogenic Shock Acute","Bypass, Cardiopulmonary","Septic Shock","Mechanical Circulatory Support","Cardiogenic Shock Post Myocardial Infarction",[568,176,565,569,570,571],"VA-ECMO","Vasopressor","Mixed Cardiogenic Shock","post cardiotomy shock","2026-01-15",{"date":574,"type":40},"2026-01-21",{"date":576,"type":40},"2025-10-20",{"date":578,"type":21},"2027-06-01",{"name":580,"class":47},"Centre Hospitalier Universitaire, Amiens",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":588,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":48},"100620209","the-application-of-t1-mapping-in-real-world-100620209","NCT07354646","The Application of T1 Mapping in Real-World","The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort","Inclusion Criteria:\n\n1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.\n2. Specific disease categories include:\n\n   * Cardiomyopathies (HCM, DCM, RCM, ACM)\n   * Infiltrative disorders (cardiac amyloidosis, Fabry disease)\n   * Inflammatory conditions (acute\u002Fchronic myocarditis)\n   * Ischemic heart disease (acute\u002Fchronic MI)\n   * Valvular heart disease (aortic stenosis)\n   * Arrhythmic conditions (atrial fibrillation)\n   * Metabolic disorders (iron-overload)\n   * Neoplastic conditions (cardiac tumors)\n   * Congenital heart disease\n   * Post-transplant evaluation\n3. All diagnoses must be confirmed using established guideline-based criteria:\n\n   * Echocardiographic parameters meeting disease-specific cutoffs\n   * Cardiac MRI findings consistent with current consensus criteria\n   * Laboratory biomarkers supporting respective diagnoses\n   * Histopathological confirmation when clinically indicated\n\nExclusion Criteria:\n\n* Presence of multiple cardiomyopathy diseases or risk factors simultaneously\n* Contraindications to CMR examination\n* Poor image quality precluding accurate T1 mapping analysis\n* Incomplete clinical data for definitive diagnosis confirmation\n* Pregnancy or lactation\n* Inability to provide informed consent",true,{"count":590,"type":21},2000,"The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:\n\nWhat are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler \"native T1\" measurement (without contrast dye) instead of the more complex \"ECV\" measurement (which requires contrast dye) for diagnosis?\n\nPatients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping",[28,593,594,595,596],"Hypertrophic Cardiomyopathy (HCM)","Dilated Cardiomyopathy (DCM)","Arrhythmogenic Cardiomyopathy","Myocarditis","2026-01-12",{"date":574,"type":40},{"date":600,"type":40},"2020-03-01",{"date":602,"type":21},"2026-12-01",{"name":604,"class":47},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":22,"phases":615,"briefSummary":616,"conditions":617,"keywords":618,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":138},"100617592","phase-3-efficacy-of-montelukast-on-steml-patients-100617592","NCT07320625","Efficacy of Montelukast on STEMl Patients","Clinical Therapeutic Efficacy of Montelukast on Anterior STEMl Patients With Primary Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. Age \\> 18 years and \\\u003C 75 years;\n2. Diagnosed with acute anterior ST-segment elevation myocardial infarction and planned to undergo primary percutaneous coronary intervention;\n3. Time from symptom onset ≤ 12 hours;\n4. The patient and their family members voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Cardiogenic shock, severe heart failure (Killip Class IV), or structural complications such as papillary muscle rupture;\n2. Having received cardiopulmonary resuscitation ;\n3. Severe and inadequately controlled hypertension (systolic blood pressure \\> 180 mmHg and\u002For diastolic blood pressure \\> 110 mmHg);\n4. Severe liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding three times the upper limit of normal) or renal dysfunction (estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²);\n5. History of myocardial infarction;\n6. Concomitant active bleeding or visceral hemorrhage;\n7. Concomitant malignant tumors, lymphomas, leukemias, or other diseases with an expected survival time of less than 1 year;\n8. Having undergone gastrointestinal surgery within the past 4 weeks that may affect the absorption of the investigational drug;\n9. Pregnant or breastfeeding women;\n10. Family history of psychiatric disorders;\n11. Having been enrolled in another drug study within the past 4 weeks or currently receiving any investigational treatment other than the study drug;\n12. Allergic to montelukast or having used montelukast within the past 4 weeks;\n13. Unable to tolerate cardiac magnetic resonance imaging (e.g., patients with magnetic materials in the body or those with claustrophobia).","75 Years",{"count":614,"type":21},512,[406],"Acute myocardial infarction (AMI) is one of the leading causes of patient mortality worldwide. Each year, over 8 million people globally die from AMI, with approximately 30% of these cases being ST-segment elevation myocardial infarction (STEMI). Despite the continuous development of reperfusion therapy strategies in recent years, which have benefited countless STEMI patients, studies have shown that even when STEMI patients receive primary percutaneous coronary intervention (pPCI) within the therapeutic time window, the in-hospital mortality rate remains as high as 4%, while the one-year post-discharge mortality rate reaches 10%. Among the survivors, about 20% further progress to heart failure.\n\nMyocardial ischemia-reperfusion injury (I\u002FRI) is the primary pathological mechanism underlying the residual risk in STEMI patients following pPCI treatment, directly influencing disease progression and clinical outcomes. Therefore, cardiac protection strategies aimed at targeted improvement of myocardial I\u002FRI to enhance patient prognosis are of paramount importance. In recent research, we have identified and elucidated a novel mechanism by which ALDH2 gene deficiency exacerbates I\u002FRI through the ER stress\u002FMgst2\u002FLTC4 signaling pathway, mediating the formation of neutrophil extracellular traps (NETosis). Furthermore, we discovered that the use of leukotriene C4 (LTC4) receptor antagonists can effectively block the ER stress\u002FMgst2\u002FNETosis myocardial injury axis, thereby significantly reducing infarct size and improving cardiac function in I\u002FRI model mice. In clinical cohorts, we observed a significant elevation in LTC4 levels during the acute phase in STEMI patients receiving pPCI. More importantly, elevated LTC4 levels were closely associated with the occurrence of left ventricular adverse remodeling and poor cardiovascular prognosis, suggesting that effective inhibition of the LTC4-related myocardial injury axis during the acute phase of myocardial infarction could yield direct clinical benefits. This highlights the critical role of LTC4 in I\u002FRI and the clinical potential of targeted LTC4 receptor therapy strategies.\n\nMontelukast is a potent leukotriene receptor antagonist with proven preventive and therapeutic effects on asthma, allergic rhinitis, and chronic obstructive pulmonary disease. In recent years, the drug repurposing strategy of montelukast in cardiovascular diseases has garnered increasing attention. Researchers have found that montelukast is closely associated with a reduced risk of major adverse cardiovascular events, indicating its therapeutic potential in cardiovascular diseases. On the other hand, mechanistic studies have also revealed that montelukast can significantly improve infarct size and ventricular remodeling levels in myocardial infarction model mice by blocking leukotriene receptors. A meta-analysis, which combined data from 26 animal experiments and 2 clinical studies, suggested that montelukast holds promising application prospects in reducing the risk of adverse cardiovascular events. Based on these findings, we propose that the drug repurposing strategy of montelukast may represent an effective treatment approach for STEMI patients. We hypothesize that in patients with anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, the application of montelukast can reduce myocardial ischemia-reperfusion injury, thereby improving ventricular remodeling and cardiac function, and exerting cardiac protective effects.",[28],[619,35,620],"montelukast","primary percutaneous coronary intervention","2026-01-11",{"date":623,"type":40},"2026-01-13",{"date":625,"type":21},"2026-02-01",{"date":627,"type":21},"2027-05-01",{"name":629,"class":47},"Shanghai Zhongshan Hospital",{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":639,"conditions":640,"keywords":642,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":48},"100619992","cmr-prognostic-markers-in-ischemic-heart-disease-100619992","NCT07351825","CMR Prognostic Markers in Ischemic Heart Disease","Prognostic Value of Multiparametric Cardiovascular Magnetic Resonance in Patients With Ischemic Heart Disease: A Multicenter Retrospective Cohort Study","Inclusion Criteria:\n\n1. Adults (≥18 years of age).\n2. Patients with ischemic heart disease, including prior or recent myocardial infarction, who underwent clinically indicated cardiac magnetic resonance (CMR) imaging.\n3. Availability of analyzable CMR images, including but not limited to cine imaging, late gadolinium enhancement (LGE), and parametric mapping sequences (T1 and\u002For T2 mapping), as applicable.\n4. Availability of baseline clinical data and longitudinal follow-up information.\n\nExclusion Criteria:\n\n1. Poor image quality or incomplete CMR data precluding quantitative analysis.\n2. Presence of other severe comorbid conditions expected to significantly affect survival or clinical outcomes.\n3. Missing key clinical outcome data during follow-up.",{"count":638,"type":21},1000,"Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide. Accurate risk stratification is essential for guiding clinical management and improving long-term outcomes in patients with ischemic myocardial injury.\n\nCardiovascular magnetic resonance (CMR) imaging provides comprehensive assessment of myocardial structure, function, and tissue characteristics, enabling detailed evaluation of ischemic injury and its consequences.\n\nThis multicenter, retrospective observational study aims to investigate the prognostic value of multiparametric CMR-derived imaging markers in patients with ischemic heart disease who underwent clinically indicated CMR examinations. Imaging parameters of interest include late gadolinium enhancement (LGE), infarct size, microvascular obstruction (MVO), left ventricular and left atrial strain, and native T1 and T2 mapping values.\n\nLong-term clinical outcomes will be obtained from existing medical records. The primary outcome is major adverse cardiovascular and cerebrovascular events (MACCE), and secondary outcome is cardiovascular death. This study seeks to clarify the role of CMR in long-term risk stratification of patients with ischemic heart disease.",[641,28],"Ischemic Heart Disease (IHD)",[643,644,645,646,647,648],"Ischemic heart disease","Cardiovascular magnetic resonance","Late gadolinium enhancement","Radiomics","Risk stratification","Prognosis",{"date":650,"type":40},"2026-01-20",{"date":652,"type":40},"2009-01",{"date":654,"type":21},"2035-12",{"name":604,"class":47},{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":664,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":665,"conditions":666,"keywords":669,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":680,"locationsCount":682},"100617338","norwegian-spontaneous-coronary-artery-dissection-study-100617338","NCT07317323","Norwegian Spontaneous Coronary Artery Dissection Study","Norwegian Spontaneous Coronary Artery Dissection Study (NOR-SCAD Study)","NOR-SCAD","Inclusion Criteria:\n\n* Spontaneous coronary artery dissection\n\nExclusion Criteria:\n\n* Severe kidney failure\n* Severe allergic reaction to contrast",{"count":460,"type":21},"The Norwegian Spontaneous Coronary Artery Dissection Study (NOR-SCAD) is a national, multicenter prospective observational study conducted at major hospitals in Norway. The study investigates risk factors and complications of spontaneous coronary artery dissection (SCAD). Patients aged 18 years or older who are hospitalized with SCAD are recruited during the index hospitalization. Each participant will be followed for 52 weeks with scheduled visits at 8 and 12 weeks and a final phone call at 52 weeks. Evaluations include coronary CT angiography (CTA), cardiac assessments, genetic analyses, blood sampling, structured questionnaires, and a cardiopulmonary exercise test (CPET).",[667,28,668],"SCAD","Women",[670,662,671,672],"SCAD NORGE","Spontan Koronar arteriedisseksjon studie","Norwegian Spontaneous Coronary artery dissection study","2025-12-18",{"date":675,"type":40},"2026-01-05",{"date":677,"type":40},"2025-04-01",{"date":679,"type":21},"2035-12-31",{"name":681,"class":47},"Oslo University Hospital",3,{"id":684,"slug":685,"hasResults":12,"nctId":686,"briefTitle":687,"officialTitle":687,"acronym":4,"eligibilityCriteria":688,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":689,"targetDuration":691,"studyType":149,"phases":4,"briefSummary":692,"conditions":693,"keywords":694,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":695,"lastUpdatePostDateStruct":696,"startDateStruct":698,"completionDateStruct":700,"leadSponsor":702,"locationsCount":48},"100612174","enhanced-prediction-model-for-major-adverse-events-following-acute-myocardial-infarction-100612174","NCT07250152","Enhanced Prediction Model for Major Adverse Events Following Acute Myocardial Infarction","Inclusion Criteria:\n\n1. Age ≥18 years old\n2. Presented with myocardial infarction, including NSTEMI and STEMI\n3. Undergoing successful percutaneous coronary intervention.\n\nExclusion Criteria:\n\n1. Subjects who decline protocol-mandated follow-up or withhold informed consent.\n2. Individuals whose expected survival is \\\u003C 1 year.",{"count":690,"type":21},1544,"60 Months","Acute myocardial infarction (AMI) remains a leading cause of mortality worldwide. Although early revascularization has markedly improved short-term outcomes, the incidence of major adverse cardiovascular events after the index event remains unacceptably high, posing a formidable clinical challenge. Contemporary risk-stratification instruments rely predominantly on a restricted set of conventional clinical variables and therefore fail to capture the full spectrum of individual pathophysiological complexity. To overcome these limitations, the present investigation aims to develop a post-AMI prognostic model that integrates comprehensive multimodal data.",[28],[35],"2025-11-18",{"date":697,"type":40},"2025-11-26",{"date":699,"type":21},"2025-12-01",{"date":701,"type":21},"2028-12-31",{"name":703,"class":47},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":705,"slug":706,"hasResults":12,"nctId":707,"briefTitle":708,"officialTitle":709,"acronym":710,"eligibilityCriteria":711,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":712,"enrollmentInfo":713,"targetDuration":4,"studyType":22,"phases":715,"briefSummary":716,"conditions":717,"keywords":721,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":695,"lastUpdatePostDateStruct":727,"startDateStruct":729,"completionDateStruct":731,"leadSponsor":733,"locationsCount":735},"100611427","endo-epicardial-versus-endocardial-only-catheter-ablation-for-ischemic-driven-ventricular-tachycardia-episode-vt-100611427","NCT07240441","Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT)","Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT) - Multicenter, Prospective, Randomized Trial","EPISODE_VT","Inclusion Criteria:\n\n* Status after myocardial infarction (minimum 3 months before inclusion in the study).\n* Documented post-infarction VT or VF.\n* Implantable ICD (at least 2 weeks before ablation) or CRT-D (at least 2 months before ablation).\n* A history of at least one from below:\n\n  1. One or more high energy interventions.\n  2. Three or more adequate antitachycardia pacing therapies, including one symptomatic.\n  3. Three or more episodes of VT in 24 hours (interrupted by ATP or shock) - electrical storm.\n  4. Sustained VT recorded on ECG with a cycle length longer than the ICD detection threshold.\n* Age between 18 and 85 years.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Obesity with BMI \\> 40 kg\u002Fm2.\n* Left ventricle ejection fraction \\\u003C 20%.\n* Pregnancy or breastfeeding.\n* Renal failure (eGFR \\\u003C 20 mL\u002Fmin\u002F1.73m2).\n* Fresh ballot thrombus in the left ventricle.\n* Suspicion of massive adhesions in the pericardium that may impede pericardial puncture.\n* Ablation of the post-infarction VT in the left ventricle in medical history.\n* Previous heart surgery.\n* Acute conditions that prevent ablation (including active infection, overt hyperthyroidism and others listed below).\n* Active neoplastic disease.\n* Heart failure with NYHA IV.\n* Life expectancy less than 12 months.","85 Years",{"count":714,"type":21},220,[24],"The EPISODE VT trial is designed to compare efficacy and safety of two modalities for interventional treatment - endocardial ablation and endo-epicardial ablation in a population of patients with post myocardial infarction (ICD 10 - I25.2) ventricular tachycardias (ICD 10 - I47.2), who are protected by an implantable cardioverter-defibrilator (ICD) and meet study inclusion criteria.",[718,28,719,720],"Ventricular Tachycardias","Implantable Cardiac Defibrillator","Ablation",[722,35,723,724,725,726],"ventricular tachycardia","epicardial access","pericardial sac puncture","ablation","implantable cardioverter defibrillator",{"date":728,"type":40},"2025-11-20",{"date":730,"type":40},"2025-02-03",{"date":732,"type":21},"2030-11-30",{"name":734,"class":47},"MEDICOVER SP Z O.O.",9]